Business
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
- Significantly Reduced Mean Annualized Bleeding Rate by 84%
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"- Significantly Reduced Mean Annualized Bleeding Rate by 84% (p-value","length":73,"tagName":"div"}]